Reporting owner · CIK 0001528185
Torley Helen
SEC Form 4 history across 1 companies, 48 transactions and 3 filings.
PRESPRESIDENT AND CEOHALOZYME THERAPEUTICS, INC.
Open-market transaction mix0% buys0 buys · 30 sales
Available history · Aug 17, 2026 – Oct 08, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$22.1kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$1.30MView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$336kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$520kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedSEC filing ↗ | $368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$22.7kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$101kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$1.15MView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$954kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedSEC filing ↗ | $368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$197kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$1.09MView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$656kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | S · sale10b5-1 detectedSEC filing ↗ | -$248kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedSEC filing ↗ | $368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$368kView disclosure → | |
HALOHALOZYME THERAPEUTICS, INC. | Torley HelenPRES | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$368kView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
sale at HALOZYME THERAPEUTICS, INC. on Oct 08, 2026 valued at $22,102.
Review SEC filingLatest buy
No open-market insider purchase is available.
Monthly open-market activity
Last 3 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 0 | 11 | $0.00 | $6,275,591.92 | -$6,275,591.92 |
| Sep 2026 | 0 | 7 | $0.00 | $6,436,711.39 | -$6,436,711.39 |
| Oct 2026 | 0 | 12 | $0.00 | $6,610,500.79 | -$6,610,500.79 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$644.1K
Median P/S size$585.1K
Direct48
Indirect0
Oct 08, 2026exercise
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No open-market purchases in available history
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
39 observations · Aug 17, 2026 – Oct 8, 2026. Window ends at the latest available report, not today.
Selected observation · Oct 8, 2026767,780 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 17, 2026 | 787,780 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 786,880 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 786,380 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 784,280 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 775,280 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 767,780 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 787,780 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 782,077 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 777,180 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 767,780 | Aug 20, 2026 | View transaction |
| Aug 19, 2026 | 787,780 | Aug 20, 2026 | View transaction |
| Aug 19, 2026 | 780,580 | Aug 20, 2026 | View transaction |
| Aug 19, 2026 | 770,980 | Aug 20, 2026 | View transaction |
| Aug 19, 2026 | 767,780 | Aug 20, 2026 | View transaction |
| Sep 9, 2026 | 787,780 | Sep 12, 2026 | View transaction |
| Sep 9, 2026 | 774,476 | Sep 12, 2026 | View transaction |
| Sep 9, 2026 | 767,880 | Sep 12, 2026 | View transaction |
| Sep 9, 2026 | 767,780 | Sep 12, 2026 | View transaction |
| Sep 10, 2026 | 787,780 | Sep 12, 2026 | View transaction |
| Sep 10, 2026 | 773,192 | Sep 12, 2026 | View transaction |
| Sep 10, 2026 | 767,780 | Sep 12, 2026 | View transaction |
| Sep 11, 2026 | 787,780 | Sep 12, 2026 | View transaction |
| Sep 11, 2026 | 772,288 | Sep 12, 2026 | View transaction |
| Sep 11, 2026 | 767,780 | Sep 12, 2026 | View transaction |
| Oct 6, 2026 | 787,780 | Oct 8, 2026 | View transaction |
| Oct 6, 2026 | 785,480 | Oct 8, 2026 | View transaction |
| Oct 6, 2026 | 779,480 | Oct 8, 2026 | View transaction |
| Oct 6, 2026 | 769,560 | Oct 8, 2026 | View transaction |
| Oct 6, 2026 | 767,780 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 787,780 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 779,180 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 768,880 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 767,980 | Oct 8, 2026 | View transaction |
| Oct 7, 2026 | 767,780 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 787,780 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 782,970 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 779,880 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 767,980 | Oct 8, 2026 | View transaction |
| Oct 8, 2026 | 767,780 | Oct 8, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Torley Helen Insider Activity FAQ
SEC Form 4 context
Who is Torley Helen?
Torley Helen is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001528185.
Which companies has Torley Helen reported transactions for?
HALOZYME THERAPEUTICS, INC.
When was Torley Helen's latest insider buy?
No open-market insider purchase is available for this period.
When was Torley Helen's latest insider sale?
sale at HALOZYME THERAPEUTICS, INC. on Oct 08, 2026 valued at $22,102.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.